What Therapeutic Class of Drugs Do You Think Dominated the Market in 2017?

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses which drugs are expected to dominate the market in 2017.

Ogurchak: In 2017, I really don’t foresee there being any 1 therapeutic class that’s going to dominate the market like we saw with hep C over the last few years.

What we’re seeing is a number of new therapies coming to the market that often target novel sorts of conditions. So, where we used to see a large target for HIV or a large target for hep C, we’re likely going to see more and more therapies that are disjointed that don’t fall into a therapeutic class but it’s still providing a number of new opportunities to patients where there may not have been a solution otherwise.